tweenvest

Bio-Rad Laboratories, Inc. (NYSE: BIO)

Salud · Herramientas y servicios para ciencias de la vida · US

370,17 $

+3,34 % hoy · +20,3 % 1 año

Ficha pública
Un resumen gratuito de Bio-Rad Laboratories, Inc., con datos del 15 nov 2026. El análisis completo está en la app.Abrir en la app

Bio-Rad Laboratories, Inc. (NYSE: BIO) opera en la industria de herramientas y servicios para ciencias de la vida dentro del sector salud. Su valor en bolsa es de 10,06 mil M $ y tiene 7450 empleados.

En los últimos doce meses la acción ha subido un 20,3 % y ha cotizado entre 236,73 y 396,23.

Tweenvest puntúa a Bio-Rad Laboratories, Inc. en cuatro factores: calidad 78/100, valor 35/100, crecimiento 30/100. Su punto más fuerte es calidad.

Evolución de la cotización de BIO

21 nov 2025 · 316,70Cierres semanales 247,53 – 387,7018 nov 2026 · 370,17

Cifras clave

Capitalización
10,06 mil M $
Ingresos (últ. 12 m)
2,59 mil M $
PER
9,73
BPA
37,97
Rent. por dividendo
—
Beta (5 años)
1,06
Máximo 52 semanas
396,23 $
Mínimo 52 semanas
236,73 $
Volumen medio (3 m)
—
Acciones en circulación
26,89 M
Empleados
7450
Próximos resultados
—

Sobre Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

ISIN
US0905722072
Fundada en
1952
Cotiza desde
27 feb 1980
Bolsa
New York Stock Exchange
Divisa
USD
EmpresaCapitalizaciónPrecioDía
Repligen CorporationNasdaqGS: RGEN11,04 mil M $172,67 $+6,45 %
Pharmaron Beijing Co., Ltd.SZSE: 30075910,67 mil M $42,43 CN¥-3,92 %
Avantor, Inc.NYSE: AVTR10,41 mil M $15,37 $+1,25 %
Qiagen N.V.NYSE: QGEN10,23 mil M $49,56 $-0,38 %
Bruker CorporationNasdaqGS: BRKR9,66 mil M $63,26 $+3,10 %
Genscript Biotech CorporationSEHK: 15488,61 mil M $29,62 HK$-2,82 %
10x Genomics, Inc.NasdaqGS: TXG7,51 mil M $57,07 $+1,37 %
Bachem Holding AGSWX: BANB7,05 mil M $79,70 CHF+0,44 %

Ver todas las empresas de herramientas y servicios para ciencias de la vida →